A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Ciclopirox

First FDA approval2007-09-18
Generic availableYes · 11 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$41.5M in CY2024 Part D spend1.4M claims · 752K beneficiaries · 329 plans surveyed

Lowest NADAC
$0.318/unit
13 NDCs benchmarked, lowest of all strengths.
Average NADAC
$1.38
Across all dosage forms in distribution.
Highest NADAC
$7.35
Wide spread — brand-strength NDCs still in market.
Plans with PA
20 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema8 entries indexed · 4 visible
What is Ciclopirox used for?

Ciclopirox is a this drug class medication tracked in Medicare Part D.

Is there a generic for Ciclopirox?

Yes. 20 ANDAs filed at FDA, 11 generic manufacturers currently shipping.

How much does my plan pay for Ciclopirox?

Across 329 Part D plans, Ciclopirox averages $1.38/unit (NADAC). Lowest available: $0.318/unit. Highest in distribution: $7.35/unit.

Is Ciclopirox on the FDA shortage list?

No. Ciclopirox is not currently on the FDA Drug Shortage Database.

4 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (13 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.